Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

NCT01046630 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Depression

Interventions

DRUG: AZD6765
DRUG: Ketamine
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]